Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

Conversation with Ryan Field, the CEO of Kernel | Psychedelic Industry Interview Series

September 25, 2023

Diving Into Exciting Emerging Sectors With Cody Shandraw

The Dales Report brings you another psychedelic exclusive. Today we talk to entrepreneur Cody Shandraw, Managing Partner at Ambria Capital & Phyto Partners IV, about

September 18, 2023

Preconception intake of calcium and zinc linked to lower risk of hypertensive disorders of pregnancy

People with higher intakes of calcium and zinc in the three months before they conceived were significantly less likely to suffer hypertensive disorders during their

June 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.